6 Mar 2024 07:00
REDX PHARMA PLC
("Redx" or the "Company")
Redx to Exhibit Three Posters at AACR Annual Meeting
Poster in collaboration with Garvan Institute of Medical Research to present pre-clinical data demonstrating potential of zelasudil in pancreatic ductal adenocarcinoma
Pre-clinical data highlights potential of combining zamaporvint with MAPK pathway inhibitors in gastrointestinal cancer
Presentation of final data from zamaporvint Phase 1 programme
Alderley Park, UK, 6 March 2024 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, targeted therapeutics for the treatment of fibrotic disease and cancer today announces that three abstracts submitted by the Company have been accepted for presentation as posters at the 2024 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, 5 - 10 April 2024.
One poster investigating Redx's lead asset zelasudil (RXC007), a selective ROCK 2 inhibitor, currently in Phase 2a development for Idiopathic Pulmonary Fibrosis (IPF) which has shown promising preclinical efficacy in a range of models, will be presented in collaboration with the Company's research partner, the Garvan Institute of Medical Research, Australia The data from preclinical models of pancreatic cancer shows the potential of zelasudil to increase survival in mouse models of pancreatic ductal adenocarcinoma (PDAC), when used in combination with current standard of care.
Redx will also present two posters on zamaporvint (RXC004) a potent and selective porcupine inhibitor targeting Wnt-ligand dependent cancers, currently in Phase 2 development in hard-to-treat tumors. The first poster highlights the potential to combine zamaporvint with MAPK pathway inhibitors in gastrointestinal cancer models showing that co-inhibition of these pathways leads to synergistic effects in vitro and enhanced efficacy in vivo. The second poster, entitled: Final results of the first-in-human study of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with advanced solid tumors, will discuss final data from all the Phase 1 modules of the programme. The abstract from this second poster will be available on 5 April 2024 at 3:00pm ET.
Richard Armer, Chief Scientific Officer, Redx Pharma commented: "To have three poster presentations at a prestigious conference such as AACR is a testament to the strength of our portfolio. With the potential to expand the indications for zelasudil beyond IPF and interstitial lung diseases into fibrotic cancers such as pancreatic; and the expansion of potential combination treatments with zamaporvint for hard-to-treat aggressive tumours, we are optimistic about the utility of our drugs for a number of underserved patient populations."
Details of the poster presentations are as follows:
Zelasudil (RXC007)
Abstract Title: | Combining Zelasudil, a small molecule ROCK2 inhibitor, with chemotherapy or immunotherapy improves response in preclinical models of Pancreatic cancer |
Session Title: | Tumor Microenvironment |
Date/Time: | Sunday Apr 7, 2024 1:30 PM - 5:00 PM |
Location: | Poster Section 29 |
Poster Board Number: | 6 |
Published Abstract Number: | 720 |
Zamaporvint (RXC004)
1)
Abstract Title: | Pre-clinical activity of the Wnt pathway inhibitor RXC004 in combination with MAPK pathway inhibitors in GI cancer models |
Session Title: | Application of Precision Medicine for Cancer Care |
Date/Time: | Sunday Apr 7, 2024 1:30 PM - 5:30 PM |
Location: | Poster Section 39 |
Poster Board Number: | 12 |
Published Abstract Number: | 944 |
2)
Abstract Title: | Final results of the first-in-human study of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with advanced solid tumors |
Session Title: | First-in-Human Phase I Clinical Trials 1 |
Date/Time: | Monday Apr 8, 2024 1:30 PM - 5:30 PM |
Location: | Poster Section 48 |
Poster Board Number: | 9 |
Published Abstract Number: | CT101 |
For further information, please contact: |
| |||||
| ||||||
Redx Pharma Plc UK Headquarters Caitlin Pearson, Head of Communications ir@redxpharma.com
| T: +44 (0)1625 469 918 |
| ||||
SPARK Advisory Partners (Nominated Adviser) | T: +44 (0)203 368 3550 |
| ||||
Matt Davis/ Adam Dawes |
| |||||
| ||||||
WG Partners LLP (Joint Broker) | T: +44 (0)203 705 9330 |
| ||||
Claes Spång/ Satheesh Nadarajah/ David Wilson |
| |||||
| ||||||
Panmure Gordon (UK) Limited (Joint Broker) | T: +44 (0)207 886 2500 |
| ||||
Rupert Dearden/ Freddy Crossley/ Emma Earl |
| |||||
| ||||||
FTI Consulting | T: +44 (0)203 727 1000 |
| ||||
Simon Conway/ Ciara Martin |
| |||||
About Redx Pharma Plc
Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted therapeutics for the treatment of fibrotic disease, cancer and the emerging area of cancer-associated fibrosis. Redx aims to progress its programmes to clinical proof of concept before evaluating options for further development and potential value creation. The Company's lead fibrosis product candidate, the selective ROCK2 inhibitor, zelasudil (RXC007), is in development for interstitial lung disease and is undergoing a Phase 2a trial for idiopathic pulmonary fibrosis (IPF) with topline data expected in H1 2024. The Company's second fibrosis candidate, RXC008, a GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, is in Phase 1 development with healthy volunteer data expected by the end of 2024. Redx's lead oncology product candidate, the Porcupine inhibitor zamaporvint (RXC004), being developed as a targeted treatment for Wnt-ligand dependent cancers, is expected to report anti-PD-1 combination Phase 2 data during the first half of 2024, following which Redx will seek a partner for ongoing development.
The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its wholly-owned clinical-stage product candidates and discovery pipeline, but also by its strategic transactions, which includes the sale of pirtobrutinib (RXC005, LOXO-305), the only non-covalent or reversible BTK inhibitor now approved by the US FDA, and transactions with both AstraZeneca and Jazz Pharmaceuticals.
To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/.